Evidence map›Paper›PMID 41769084›Full record

ArticleCase reports in hepatology2026

Prolonged Terlipressin Therapy as a Bridge to Curative TIPS for HRS-AKI in a Nontransplant Candidate.

Deirdre Reidy, Arun Jesudian, David Salerno, Catherine Lucero

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Deirdre ReidyDepartment of Internal Medicine, Weill Cornell Medicine, New York, 10021, New York, USA, cornell.edu.ORCID https://orcid.org/0000-0002-8102-4068
Arun JesudianDivision of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, 10065, New York, USA, cornell.edu.
David SalernoDepartment of Pharmacy, NewYork-Presbyterian Hospital, New York, 10021, New York, USA.
Catherine LuceroDivision of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, 10065, New York, USA, cornell.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a severe complication of advanced cirrhosis with high mortality and limited treatment options. Terlipressin is currently the only FDA-approved therapy for HRS, though recurrence is common upon discontinuation in patients without access to liver transplantation. Transjugular intrahepatic portosystemic shunt (TIPS) may provide definitive treatment for HRS-AKI in nontransplant candidates or in the setting of prolonged waitlists. This case illustrates the safety and success of terlipressin prior to TIPS for definitive treatment of HRS-AKI in a nontransplant candidate.

Identifiers

PMID41769084
PMCPMC12947108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.